QNCX

Quince Therapeutics, Inc.

0.71 USD
+0.01 (+1.02%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Quince Therapeutics, Inc. stock is down -22.53% since 30 days ago. The next earnings date is Aug 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 20 June’s closed higher than May.

About Quince Therapeutics, Inc.

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor.